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It is now well established that symptoms of Alzheimer’s 
disease (AD) dementia are preceded by a long period of 
gradual accumulation of pathological changes [1]. Th  e 
growing view that disease-modifying therapies may only 
be eﬀ  ective if used relatively early in this process has 
shifted attention towards the pre-dementia phases of the 
disease. Th  is shift in focus has been accompanied by 
increasing recognition of the importance of familial AD. 
Th   e study of individuals carrying rare, autosomal domi-
nantly inherited mutations in the amyloid precursor protein 
(APP), Presenilin 1 (PSEN1) and Presenilin 2 (PSEN2) 
genes provides unique opportunities to observe the 
earliest manifestations of the pathological process. With 
the design of prevention trials for these individuals already 
underway [2,3], there is an urgent need to better under-
stand and deﬁ  ne the pre-dementia stages of familial AD.
Acosta-Baena and colleagues recently reported the 
results from their 15-year study of a Colombian kindred 
aﬀ   ected by the E280A PSEN1 mutation [4]. Of 1,784 
family members enrolled, 1,181 were genotyped yielding 
459 carriers and 722 noncarriers. Of the carriers, 449 had 
undergone neuropsychological testing; 140 (31%) were 
assessed only once, whilst the remainder had serial assess-
ments (average 3.2 assessments, range 1 to 12) at intervals 
ranging from 1 to 11 years (mean 2.1 years). Th  e  neuro-
psychological data from 499 of the noncarriers were used 
to generate normal parameters for the Colombian popu-
lation under the age of 50, which were grouped according 
to age and education.
Th   e authors deﬁ  ned  ﬁ   ve clinical states: healthy, 
dementia, and three intermediate stages of pre-dementia 
cognitive impairment [4]. Pre-dementia cognitive impair-
ment was deﬁ  ned as a score 2 standard deviations away 
from the noncarrier mean, adjusted for age and educa-
tion, on at least one cognitive test. Th  ose patients with 
pre-dementia cognitive impairment but no memory 
complaints were deﬁ   ned as asymptomatic pre-mild 
cogni  tive impairment (pre-MCI). Th  ose patients with 
memory complaints and a score higher than the non-
carrier mean on a subjective memory complaints 
checklist, but with little or no impairment of complex 
activities of daily living (ADL), were deﬁ  ned as MCI. In 
between, a stage of symptomatic pre-MCI deﬁ  ned those 
individuals who had some memory complaints but did 
not score higher than the noncarrier mean on the 
subjective memory complaints checklist, with preserved 
ADL. Individuals with memory complaints interfering 
with complex and basic ADL were deﬁ  ned as demented. 
Using survival analyses to model progression, the authors 
described a typical trajectory from healthy to asympto-
matic pre-MCI (median age at onset 35 years), to sym  p-
to  matic pre-MCI (median age 38 years), to MCI (median 
age 44 years), to dementia (median age 49 years) and 
ultimately to death (median age 59 years). Th  e  cognitive 
Abstract
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the natural history of the illness has never been so 
important. Earlier this year in The Lancet Neurology, 
Acosta-Baena and colleagues published the results 
of the largest and longest retrospective study of 
pre-dementia clinical stages in familial Alzheimer’s 
disease to date. By reviewing serial neuropsychological 
assessments of individuals from a large Colombian 
kindred aff  ected by the E280A mutation in the 
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dementia cognitive impairment. Using survival 
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study provides valuable insights into the time course 
of cognitive decline associated with this mutation. 
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challenges of defi  ning pre-dementia clinical stages in 
familial Alzheimer’s disease and the need for the fi  eld 
to develop a consistent terminology.
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recovery noted in the symptomatic pre-MCI stage, 
followed by a continuous decline in multiple cognitive 
domains.
Given the phenotypic heterogeneity observed between 
diﬀ  erent genetic mutations associated with familial AD 
[5], Acosta-Baena and colleagues’ study of such a large 
number of individuals with the same mutation is a 
valuable addition to the literature. Th  eir framework for 
characterising the pre-dementia stages of familial AD 
does raise certain issues, however, which question how 
applicable it may be to other populations with familial 
AD and highlight the diﬃ   culties of deﬁ  ning pre-dementia 
clinical stages.
As the authors discuss, the concept of MCI was not 
widespread when they started their study and debate 
continues regarding how MCI may best be deﬁ  ned. Th  eir 
MCI deﬁ   nition resembles the Petersen criteria, which 
require the presence of memory complaints with pre-
served basic ADL and no or minimal impairment of 
complex ADL [6]. While the Petersen criterion for cogni-
tive impairment is a score 1.5 standard deviations away 
from normal values on neuropsychological tests, however, 
Acosta-Baena and colleagues deﬁ   ned impair  ment as 2 
standard deviations away. Th   ey chose this more stringent 
cut-oﬀ   value to reduce the possibility of false positives; a 
valid justiﬁ   cation, although it limits how comparable 
their results are with studies employing the Petersen 
criteria.
Comparability within the ﬁ  eld is further limited by the 
fact that many other studies do not incorporate neuro-
psychological results into their classiﬁ   cation of MCI, 
instead deﬁ   ning it as a score of 0.5 on the clinical 
dementia rating scale; a structured interview with the 
participant and a close informant [7]. As the ﬁ  eld moves 
forward and prevention trials for familial AD are 
launched, it will be crucial that diﬀ  erent studies share a 
common construct of MCI if the eﬃ   cacies of diﬀ  erent 
therapies are to be compared.
Th   e situation is more complex regarding the term pre-
MCI, which is conventionally used to describe subjective 
memory complaints without evidence of neuropsycho-
logical deﬁ  cit [8]. Acosta-Baena and colleagues, however, 
use the term pre-MCI for individuals with objective 
cognitive impairment who are either asymptomatic or 
symptomatic with a score on the subjective memory 
complaints checklist lower than the noncarrier mean. In 
some centres this symptomatic pre-MCI group would 
have been classiﬁ   ed as MCI, and the ﬁ   ndings by the 
authors of some transient recovery in the symptomatic 
pre-MCI group may be akin to the subset of MCI patients 
in other studies whose symptoms revert.
Th  e authors speculate that cognitive reserve is the 
source of the transient recovery in these individuals; 
although an alternative explanation may be that anxiety 
or depression was the cause of the initial symptoms. It is 
not unusual for individuals at risk of familial AD to 
experience considerable anxiety about the possibility of 
developing memory problems, which understandably 
accentuates as they grow close to the age at which their 
parent developed symptoms. Th  e authors’ reference to 
the subjective memory complaints scores in the non-
carriers provided one way of addressing this issue, but it 
would have also been interesting to know how the 
individuals with symptomatic pre-MCI who improved 
scored on the geriatric depression scale.
It is notable that all of the symptomatic participants in 
Acosta-Baena and colleagues’ study had objective cogni-
tive deﬁ  cits by the time they manifested symptoms. In 
our experience, not all individuals who develop familial 
AD follow the same trajectory. Whilst objective cognitive 
deﬁ  cits do manifest several years prior to symp  toms in 
many patients [9], others may develop memory com-
plaints without objective impairment initially, and would 
conform to the conventional deﬁ   nition of pre-MCI. 
Anxiety may play a role in these symptoms, or it may be 
that standard neuropsychological tests are not sensitive 
enough to detect the earliest deﬁ  cits in highly educated 
participants. Th   e low education level in the current study 
(>50% had <6 years of education) may limit the 
generalisa  bility of the results to other populations aﬀ  ected 
by familial AD. One must also be wary of practice eﬀ  ects 
in individuals who have been participat  ing in natural 
history studies for many years. All of these factors should 
be considered as limitations when using neuro  psycho-
logical tests as the basis for deﬁ  ning stages of disease.
Much progress has been made to reﬁ  ne and incorporate 
biomarkers into deﬁ   nitions of pre-dementia stages in 
sporadic AD [10-12]. Understanding the sequence of 
biomarker changes in familial AD may, in time, contri-
bute to the characterisation of stages of disease. However, 
as biomarker abnormalities are already present in pre-
symptomatic familial AD [13-15], the interpretation of 
their signiﬁ  cance itself requires correlation with clinical 
stage. How these stages are deﬁ  ned will be inﬂ  uenced by 
the meaning that symptoms have for an individual, their 
family and sociocultural environment. Variability in these 
factors across diﬀ   erent geographical locations brings 
challenges, but the rarity of familial AD means that 
eﬀ  orts to prevent it must take a global perspective and 
start by establishing a common frame  work for deﬁ  ning 
the stages of disease.
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